BCR::ABL1

About

Biomarker type: Gene fusion

Gene context: ABL1, BCR

Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Organizations Biomarkers Cancer types Therapies
FDA (2) HC (1) BCR::ABL1 Chronic Myelogenous Leukemia Asciminib
FDA (1) ABL1 p.T315I, BCR::ABL1 Chronic Myelogenous Leukemia Asciminib
FDA (1) CD19 +, not BCR::ABL1 Acute Lymphoid Leukemia Blinatumomab
FDA (2) HC (2) BCR::ABL1 Chronic Myelogenous Leukemia Bosutinib
FDA (3) HC (2) BCR::ABL1 Chronic Myelogenous Leukemia Dasatinib
FDA (3) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Dasatinib
FDA (2) HC (1) BCR::ABL1 Acute Lymphoid Leukemia Dasatinib
FDA (2) HC (2) BCR::ABL1 Chronic Myelogenous Leukemia Imatinib
FDA (2) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Imatinib
FDA (2) HC (2) BCR::ABL1 Acute Lymphoid Leukemia Imatinib
FDA (3) HC (4) BCR::ABL1 Chronic Myelogenous Leukemia Nilotinib
FDA (3) HC (4) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Nilotinib
FDA (1) BCR::ABL1 Acute Lymphoid Leukemia Cytarabine, Dexamethasone, Methotrexate, Ponatinib, Prednisone, Vincristine
FDA (1) HC (1) ABL1 p.T315I, BCR::ABL1 Acute Lymphoid Leukemia Ponatinib
FDA (2) HC (1) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Asciminib